Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Payables (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Payables for 6 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 15.93% year-over-year to $6.4 million, compared with a TTM value of $6.4 million through Dec 2025, up 15.93%, and an annual FY2025 reading of $6.4 million, up 15.93% over the prior year.
  • Payables was $6.4 million for Q4 2025 at Cytek Biosciences, up from $6.2 million in the prior quarter.
  • Across five years, Payables topped out at $6.7 million in Q2 2022 and bottomed at $3.0 million in Q4 2023.
  • Average Payables over 5 years is $4.7 million, with a median of $4.8 million recorded in 2022.
  • The sharpest move saw Payables tumbled 54.33% in 2023, then skyrocketed 82.35% in 2024.
  • Year by year, Payables stood at $3.0 million in 2021, then soared by 58.37% to $4.8 million in 2022, then crashed by 36.9% to $3.0 million in 2023, then skyrocketed by 82.35% to $5.5 million in 2024, then rose by 15.93% to $6.4 million in 2025.
  • Business Quant data shows Payables for CTKB at $6.4 million in Q4 2025, $6.2 million in Q1 2025, and $5.5 million in Q4 2024.